Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 8/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 2/20 | 0.35 |
| ▸ | MC5R | P33032 | 2/20 | 0.35 |
| ▸ | MC3R | P41968 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867540 | 1.00 | GHSR (0.64) | GHSRPPARGPPARAMMP9MMP8 | |
| SCHEMBL29958716 | 1.00 | GHSR (0.64) | GHSRPPARGPPARAMMP9MMP8 | |
| SCHEMBL6320645 | 0.93 | GHSR (0.66) | GHSRMMP9MMP8MC4RMC5R | |
| SCHEMBL6325612 | 0.93 | GHSR (0.66) | GHSRMMP9MMP8MC4RMC5R | |
| SCHEMBL6320638 | 0.93 | GHSR (0.66) | GHSRMMP9MMP8MC4RMC5R | |
| SCHEMBL14433216 | 0.93 | GHSR (0.66) | GHSRPPARGPPARAMMP9MMP8 | |
| SCHEMBL18472634 | 0.92 | GHSR (0.65) | GHSRMMP9MMP8MC4RMC5R | |
| SCHEMBL6424310 | 0.91 | GHSR (0.60) | GHSRPPARGPPARAMMP9MMP8 | |
| SCHEMBL14003462 | 0.90 | GHSR (0.62) | GHSRMMP9MMP8 | |
| SCHEMBL3267711 | 0.90 | GHSR (0.75) | GHSRMMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1047709-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2004-11-03 | — | — | EP | claimed |
| US-6083908-A | TREATING MEDICAL DISORDERS RESULTING FROM DEFICIENCY IN GROWTH HORMONE | NOVO NORDISK A/S (DK) | 2000-07-04 | — | — | US | claimed |
| US-8394833-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394833-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394833-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8288427-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288427-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288427-B2 | Methods of treating emesis using growth hormone secretagogues | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | REJUVENON CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | REJUVENON CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20050261201-A1 | Method of reducing C-reactive protein using growth hormone secretagogues | REJUVENON CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| EP-1506969-A1 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-02-16 | — | — | EP | disclosed |
| EP-1047709-B1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2004-11-03 | — | — | EP | disclosed |
| EP-1047709-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999036431-A9 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK AS (DK) | 2000-07-27 | — | — | WO | disclosed |
| US-6083908-A | TREATING MEDICAL DISORDERS RESULTING FROM DEFICIENCY IN GROWTH HORMONE | NOVO NORDISK A/S (DK) | 2000-07-04 | — | — | US | disclosed |
| WO-1999036431-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261201-A1 | Method of reducing C-reactive protein using growth hormone secretagogues | CETP, FABP7, TGFB1 | GHSR 14/4885PPARG 88/4885PPARA 216/4885 |
| US-20120232113-A1 | METHODS OF TREATING EMESIS USING GROWTH HORMONE SECRETAGOGUES | GHSR, GHRHR, CRH | GHSR 1/4885PPARG 463/4885PPARA 1485/4885 |
| US-20070191283-A1 | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues | GHSR, GHRHR, MLNR | GHSR 1/4885PPARG 921/4885PPARA 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.